Scribd
Upload
11 views1 page

Prep Efficacy Counselling Message: Time To Protection

This document provides information about the time needed to build up protective levels of PrEP drugs in the blood and tissues. It recommends additional HIV prevention measures such as safer sexual practices for seven days after starting PrEP.

Uploaded by

jon Torres
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
11 views1 page

Prep Efficacy Counselling Message: Time To Protection

This document provides information about the time needed to build up protective levels of PrEP drugs in the blood and tissues. It recommends additional HIV prevention measures such as safer sexual practices for seven days after starting PrEP.

Uploaded by

jon Torres
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

PREP EFFICACY COUNSELLING MESSAGE:

Time to Protection
“PrEP provides high levels of protection in people who take PrEP medicines regularly. Time
is needed to build up protective levels of the drug in the blood and other tissues. Additional
HIV prevention should be taken for seven days (5, 6, 40, 44, 45). Ways to lower risk during
this period include: adopting safer sexual practices, such as not having vaginal or anal
intercourse, or using condoms for all vaginal and anal intercourse.”

WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 1:
Clinical. Geneva: World Health Organization; 2017 (WHO/HIV/2017.17). Licence: CC BY-
NC-SA 3.0 IGO.
References from WHO Implementation Tool for PrEP of HIV Infection, July 2017:

5. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-
exposure prophylaxis, sexual practices, and HIV incidence in men and transgender
women who have sex with men: a cohort study. The Lancet Infectious Diseases.
2014;14(9):820-9.

6. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand


Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med.
2015;373(23):2237-46.

40. Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al.
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure
prophylaxis in women. AIDS. 2015;29(3):331-7.

44. Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA,
et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who
have sex with men. Clin Infect Dis. 2015;60(5):804- 10.

45. Cottrell M, Yang K, Prince H, Sykes C, White N, Malone S, et al. A Translational


Pharmacology Approach to Predicting HIV Pre-Exposure Prophylaxis Outcomes in Men
and Women Using Tenofovir Disoproxil Fumarate ± Emtricitabine. J Infect Dis. 2016.

You might also like